

AUGUST 2020



Key Trends

in Tracking Supply of and Demand for Oncologists



Key Trends in Tracking Supply of and Demand for Oncologists

Table of Contents

| | |
|---|----|
| Introduction | 3 |
| Limitations of the Data | 6 |
| Section 1 - Supply | |
| Number of Oncologists Engaged in Patient Care | 6 |
| Percentage of Oncologists Who Are Female | 8 |
| Percentage of Oncologists by Age Group | 9 |
| Median Age of Oncologists | 10 |
| Number of Oncologists by State | 11 |
| Oncologists per 100,000 Residents Age 55 Years and Older | 12 |
| Size and Distribution of Oncology Practices | 14 |
| Distribution of Rural and Non-Rural Oncology Practices | 15 |
| Section 2 - New Entrants | |
| Residents in Oncology Pipeline Programs | 16 |
| Percentage of Residents in Oncology Pipeline Programs Who Are Female | 17 |
| Percentage of Residents in Oncology Pipeline Programs Who Are USMDs | 18 |
| Number of Physicians Who Completed an Oncology Pipeline Program | 19 |
| Number of Physicians Who Applied for an Internal Medicine Subspecialty Fellowship | 20 |
| Number and Percentage of USMD Oncology Fellowship Applicants Who Matched to an Oncology Fellowship | 21 |
| Number of First Year Fellows in Internal Medicine Subspecialties | 22 |
| Percentage of First Year Fellows in Internal Medicine Subspecialties by Subspecialty | 23 |
| Percentage of Fellows in Internal Medicine Subspecialties Who Are Female | 24 |
| Percentage of Residents/Fellows Who Are Female | 25 |
| Percentage of Fellows in Internal Medicine Subspecialties Who Are IMGs | 26 |
| Percentage of Fellows in Internal Medicine Subspecialties Who Are Black or African American | 27 |
| Percentage of Residents/Fellows Who Are Black or African American | 28 |
| Percentage of Fellows in Internal Medicine Subspecialties Who Are Hispanic or Latino. | 29 |
| Percentage of Residents/Fellows Who Are Hispanic or Latino. | 30 |
| New Entrants to the Oncology Workforce (Fellows Completing GME and Board Exam Test Takers) | 31 |
| Section 3 - Cancer Incidence and Prevalence | |
| Estimated Number of New Cancer Cases (in 1000s) by Sex | 32 |
| Five-Year Relative Cancer Survival Rates by Year of Diagnosis | 33 |
| Number of People With a History of Cancer (in 1000s) | 34 |



Key Trends in Tracking Supply of and Demand for Oncologists

INTRODUCTION

The Workforce Information System (WIS) builds on ASCO's 2007 workforce study that projected shortages in US oncologist supply by 2020.¹ The original study was a landmark analysis for assessing workforce capacity and predicting changes over time. One limitation, however, was that the study relied on a static snapshot of the oncologist workforce. In intervening years, major shifts in the economy, political and regulatory environments, and the healthcare system have altered the relationship between the supply of and demand for cancer services. These factors can also vary dramatically by geography. The WIS provides ASCO with an ongoing method for data collection and reporting on the current status of the oncologist workforce.

This report includes a series of figures and data tables showing trends over time and is organized into three sections: 1) Supply; 2) New Entrants; and 3) Cancer Incidence and Prevalence. It is designed so that it can be used in its entirety as one report, or as individual fact sheets. Since 2014, ASCO has presented key findings from the WIS in the State of Cancer Care in America article series in JCO Oncology Practice. The series uses a data-driven approach to examine oncology practice issues to aid the oncology community, policymakers, and others in shaping the future of cancer care in America. Visit asco.org/state-of-cancer-care to view content from the series.

In general, the report focuses on three main oncology specialties—hematology, hematology/oncology, and medical oncology—but in some cases, data are shown for other oncology specialties and other subspecialties of internal medicine. Herein, this grouping of hematology, hematology/oncology, and medical oncology is presented as "Oncology (Composite)." In many figures and tables, data for the individual specialties are presented as well.

SUPPLY

The **Supply** section of this report features data from two provider databases: the American Medical Association's (AMA) Physician Masterfile and the Centers for Medicare & Medicaid Services' (CMS) Physician Compare dataset. Permission was obtained from the AMA to use Masterfile data; however, the use and reference to AMA data by ASCO should not be construed as endorsement by the AMA, nor do the ideas or opinions expressed herein reflect the views of the AMA. Physician Compare is publicly available from data.medicare.gov.

The data in the **Supply** section focus mainly on active oncologists practicing in one of three specialty areas: hematology, hematology/oncology, or medical oncology. It is important to note that the custom tabulations are based on the physicians' primary specialty listing only. Where informative, benchmark data on "all physicians" are included as a reference.

Figures in the **Supply** section of the report that concern physician demographics (e.g., age and gender) are derived from the AMA Masterfile. The remaining figures represent geographic analyses of practice addresses registered with the Medicare program and made available through Physician Compare. Several of the maps combine practice information with US population data and other demographic attributes by geography provided by the US Census Bureau and the US Department of Agriculture. Detailed methodology is available elsewhere.²

1. Erikson C, Salsberg E, Forte G, et al: Future supply and demand for oncologists: Challenges to assuring access to oncology services. *J Oncol Pract* 3:79–86, 2007.

2. Kirkwood MK, Bruinooge SS, Goldstein MA, et al: Enhancing the American Society of Clinical Oncology Workforce Information System With Geographic Distribution of Oncologists and Comparison of Data Sources for the Number of Practicing Oncologists. *Journal Oncol Pract* 10:32-38, 2014.

Key Trends in Tracking Supply of and Demand for Oncologists

NEW ENTRANTS

This section focuses on physicians in training, starting with the pipeline of residents who are eligible to enter training in hematology, hematology/oncology, medical oncology, gynecologic oncology, and pediatric hematology/oncology fellowship programs (i.e., residents who completed an internal medicine, obstetric/gynecology, or pediatric residency program) and continuing through to the number completing training in oncology fellowship programs. In addition to demographic comparisons (such as gender, race, and ethnicity), we provide data on the competitiveness of oncology fellowships relative to other internal medicine fellowship programs. Where appropriate, we have included benchmark references of all residents, internal medicine residents, and/or select internal medicine subspecialties.

Data from this section come from three primary sources: 1) annual publications of the *Journal of the American Medical Association*'s (*JAMA*'s) Medical Education issue, 2) annual publications of the National Residency Match Program, and 3) data on first time board test-takers as published online by the American Board of Internal Medicine (ABIM).

CANCER INCIDENCE AND PREVALENCE

The **Cancer Incidence and Prevalence** section presents the latest available data on cancer incidence and prevalence, showing the trends in the number of new cases and number of survivors. Survivor data is presented in terms of five-year survival rates as well as anyone with a history of cancer.

Data for the **Cancer Incidence and Prevalence** section come primarily from two sources: 1) National Cancer Institute (NCI) publications focusing on analysis of the Surveillance Epidemiology and End Results Cancer Statistics Review, and 2) the American Cancer Society's annual publication, Cancer Facts and Figures, which is jointly prepared with the NCI.

Key Trends in Tracking Supply of and Demand for Oncologists

LIMITATIONS OF THE DATA

Much of the data from the Supply section of this report come from the AMA Physician Masterfile. Although the Masterfile was not designed for workforce analysis, it is commonly used because it captures detailed demographic and practice information for AMA member and nonmember physicians. The AMA makes the full Masterfile available to ASCO and other researchers on an annual basis. The advantage to this is researchers are afforded the flexibility to create custom tabulations of the data. For instance, data on the percentage of oncologists who are age 64 or older are only obtainable by using the Masterfile itself.

Despite the flexibility of using the full Masterfile, there are disadvantages to using it as a source of data on oncologists. A physician's activity status comes from the AMA's Census of Physicians. A physician typically receives the AMA's Census every three to four years, which may result in a lag in changing a physician's status from active to inactive. Because much of the information is self-reported through the AMA Census, there are also issues with interpretation (e.g., which specialty field a physician chooses as his/her primary specialty) and with missing fields. In addition, physician board certification information is not available through the Masterfile.

In order to assess the geographic distribution of oncologists, we used a second data source for the Supply section: the CMS Physician Compare database. Physician Compare is a publicly available data set that stores information on US healthcare providers, specifically those who have submitted a Medicare Fee-for-Service claim or enrolled in the Provider Enrollment, Chain, and Ownership System (PECOS) within the prior six months. The data are the most up-to-date available, to our knowledge, and provide individual-level addresses for physician practice locations (and secondary practice locations, where applicable). Physician Compare does not provide demographic and practice information important for workforce monitoring (e.g., age and employment setting), so cannot replace the AMA Masterfile as the primary Supply data source. Furthermore, because it stems from Medicare billing, it cannot be used to track the pediatric hematologist-oncologist workforce.


Much of the data from the New Entrant section come from JAMA. The published data in JAMA are derived from the AAMC/AMA National GME Census and represent an undercount of residents and fellows, as they do not account for late reporting. Furthermore, the GME Census represents ACGME programs only. However, there are less than 10 osteopathic GME programs in hematology and oncology, with fewer than 30 positions.

For purposes of annual tracking in the WIS, ASCO uses high-level data from the NCI and the American Cancer Society for the Cancer Incidence and Prevalence section. ASCO acknowledges that these statistics do not adequately represent demand for cancer care services in the United States. In 2014, ASCO published an updated demand methodology and projections.³

3. Yang W, Williams JH, Hogan PF, et al: Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage. *J Oncol Pract* 10:39-45, 2014.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 1a. Number of Oncologists Engaged in Patient Care (CMS Physician Compare)¹



| | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|--|--------|--------|--------|--------|--------|--------|--------|--------|
| Number of Oncologists (Composite) ² | 11,343 | 11,530 | 11,728 | 12,127 | 12,424 | 12,441 | 12,673 | 12,940 |
| Hematologists | 1,469 | 1,450 | 1,420 | 1,410 | 1,377 | 1,335 | 1,262 | 1,239 |
| Hematologists/Oncologists | 4,400 | 4,903 | 5,345 | 6,197 | 6,482 | 6,891 | 7,848 | 7,913 |
| Medical Oncologists | 4,302 | 4,291 | 4,230 | 4,151 | 4,035 | 3,940 | 3,744 | 3,674 |
| Gynecologic Oncologists | 451 | 463 | 459 | 466 | 456 | 455 | 490 | 497 |
| Radiation Oncologists | 3,991 | 4,084 | 4,181 | 4,398 | 4,391 | 4,457 | 4,624 | 4,596 |
| Surgical Oncologists | 392 | 406 | 418 | 428 | 429 | 429 | 457 | 463 |
| Annual percent change in number of: | | | | | | | | |
| Oncologists (Composite) ² | | 1.6 | 1.7 | 3.4 | 2.4 | 0.1 | 1.9 | 2.1 |
| Hematologists | | -0.4 | 0.7 | -0.5 | 2.4 | 1.4 | 4.5 | 0.4 |
| Hematologists/Oncologists | | 1.9 | 0.8 | 3.2 | 2.3 | -0.7 | 0.8 | 1.6 |
| Medical Oncologists | | 1.5 | 4.5 | 4.8 | 3.0 | 2.0 | 4.0 | 3.9 |
| Gynecologic Oncologists | | 2.2 | 1.7 | 2.0 | 2.3 | -1.7 | 1.8 | 3.1 |
| Radiation Oncologists | | 1.8 | 1.5 | 2.8 | 1.7 | 0.6 | 1.7 | 1.5 |
| Surgical Oncologists | | 4.6 | 6.0 | 6.1 | 4.3 | 2.8 | 6.0 | 2.2 |


Source: CMS Physician Compare, April 2020 update

¹ These data represent all physicians (MDs and DOs) with an oncology or hematology primary specialty and a US practice address in CMS Physician Compare. The Pediatric Hematology-Oncology specialty is not reported in Physician Compare.

² The data for oncologists include all physicians (MDs and DOs) with a primary specialty of hematology, hematology/oncology, or medical oncology in Physician Compare.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 1b. Number of Oncologists Engaged in Patient Care (AMA Masterfile)¹



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|
| Number of Oncologists (Composite) ² | 9,765 | 9,937 | 10,171 | 10,644 | 10,995 | 11,758 | 11,894 | 12,166 | 12,854 | 12,826 |
| Hematologists | 1,570 | 1,523 | 1,469 | 1,450 | 1,420 | 1,410 | 1,377 | 1,335 | 1,262 | 1,239 |
| Hematologists/Oncologists | 3,706 | 3,997 | 4,400 | 4,903 | 5,345 | 6,197 | 6,482 | 6,891 | 7,848 | 7,913 |
| Medical Oncologists | 4,489 | 4,417 | 4,302 | 4,291 | 4,230 | 4,151 | 4,035 | 3,940 | 3,744 | 3,674 |
| Gynecologic Oncologists | 443 | 444 | 451 | 463 | 459 | 466 | 456 | 455 | 490 | 497 |
| Pediatric Hematologists/Oncologists | 1,196 | 1,214 | 1,242 | 1,373 | 1,478 | 1,735 | 1,787 | 1,853 | 2,012 | 2,031 |
| Radiation Oncologists | 3,915 | 3,941 | 3,991 | 4,084 | 4,181 | 4,398 | 4,391 | 4,457 | 4,624 | 4,596 |
| Surgical Oncologists | 344 | 360 | 392 | 406 | 418 | 428 | 429 | 429 | 457 | 463 |

Annual percent change in number of:

| | | | | | | | | | | |
|--------------------------------------|------|------|------|------|------|------|------|------|------|------|
| Oncologists (Composite) ² | 2.1 | 1.8 | 2.4 | 4.7 | 3.3 | 6.9 | 1.2 | 2.3 | 5.7 | -0.2 |
| Hematologists | -1.8 | -3.0 | -3.5 | -1.3 | -2.1 | -0.7 | -2.3 | -3.1 | -5.5 | -1.8 |
| Hematologists/Oncologists | 8.1 | 7.9 | 10.1 | 11.4 | 9.0 | 15.9 | 4.6 | 6.3 | 13.9 | 0.8 |
| Medical Oncologists | -1.1 | -1.6 | -2.6 | -0.3 | -1.4 | -1.9 | -2.8 | -2.4 | -5.0 | -1.9 |
| Gynecologic Oncologists | 1.1 | 0.2 | 1.6 | 2.7 | -0.9 | 1.5 | -2.1 | -0.2 | 7.7 | 1.4 |
| Pediatric Hematologist-Oncologists | 0.7 | 1.5 | 2.3 | 10.5 | 7.6 | 17.4 | 3.0 | 3.7 | 8.6 | 0.9 |
| Radiation Oncologists | 0.8 | 0.7 | 1.3 | 2.3 | 2.4 | 5.2 | -0.2 | 1.5 | 3.7 | -0.6 |
| Surgical Oncologists | 11.3 | 4.7 | 8.9 | 3.6 | 3.0 | 2.4 | 0.2 | 0.0 | 6.5 | 1.3 |


Source: AMA Physician Masterfile, August 2018 update

1 The data shown here represent the number of physicians (MDs and DOs, excluding residents/fellows) whose major professional activity is direct patient care. The data refer to physicians active in the US only. In cases where a physician's office state was missing, the state from the preferred mailing address was used.

2 The data for oncologists include all physicians (MDs and DOs, excluding residents/fellows) who specified hematology, hematology/oncology, or medical oncology as their primary specialty on the AMA Census of Physicians.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 2. Percentage of Oncologists Who Are Female




Source: AMA Physician Masterfile, August 2018 update

1 The data shown here are based on the number of physicians (MDs and DOs, excluding residents/fellows) whose major professional activity is direct patient care and whose sex is known. The data refer to physicians active in the US only. In cases where a physician's office state was missing, the state from the preferred mailing address was used.

2 The data for oncologists include all physicians (MDs and DOs, excluding residents/fellows) who specified hematology, hematology/oncology, or medical oncology as their primary specialty on the AMA Census of Physicians.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 3. Percentage of Oncologists¹ by Age Group




| | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Number of oncologists under age 40 | 1,177 | 1,262 | 1,423 | 1,508 | 1,778 | 1,654 | 1,617 | 1,966 | 1,632 |
| Percentage of oncologists under age 40 | 11.8 | 12.4 | 13.3 | 13.7 | 15.1 | 13.9 | 13.3 | 15.3 | 12.7 |
| Number of oncologists age 64 or older | 1,504 | 1,580 | 1,799 | 1,903 | 1,984 | 2,100 | 2,236 | 2,315 | 2,524 |
| Percentage of oncologists age 64 or older | 15.1 | 15.5 | 16.9 | 17.3 | 16.8 | 17.7 | 18.4 | 18.0 | 19.7 |

Source: AMA Physician Masterfile, August 2018 update

¹ These figures represent the number of physicians (MDs and DOs, excluding residents/fellows) who specified hematology, hematology/oncology, or medical oncology as their primary specialty on the AMA Census of Physicians, whose primary activity is direct patient care, and whose age is known. The data refer to physicians who are active in the US only. In cases where a physician's office state was missing, the state from the preferred mailing address was used.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 4. Median Age of Oncologists



| | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|------|------|------|------|------|------|------|------|------|
| Median age of all physicians ¹ | 51 | 51 | 51 | 51 | 51 | 52 | 52 | 51 | 52 |
| Median age of oncologists (composite) ² | 52 | 52 | 52 | 52 | 52 | 52 | 52 | 52 | 53 |


Source: AMA Physician Masterfile, August 2018 update

1 The data shown here represent the number of physicians (MDs and DOs, excluding residents/fellows) whose major professional activity is direct patient care and whose age is known. The data refer to physicians active in the US only. In cases where a physician's office state was missing, the state from the preferred mailing address was used.

2 These figures represent the number of active physicians (MDs and DOs, excluding residents/fellows) who specified hematology, hematology/oncology, or medical oncology as their primary specialty on the AMA Census of Physicians.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 5. Number of Oncologists by State¹



Source: CMS Physician Compare (April 2020) update and US Census Gazetteer Files (2019 update)


State (Number of Oncologists): Alabama (151), Alaska (28), Arizona (253), Arkansas (87), California (1,305), Colorado (203), Connecticut (193), Delaware (41), District of Columbia (99), Florida (837), Georgia (306), Hawaii (46), Idaho (48), Illinois (532), Indiana (241), Iowa (119), Kansas (107), Kentucky (178), Louisiana (155), Maine (70), Maryland (303), Massachusetts (588), Michigan (396), Minnesota (335), Mississippi (112), Missouri (272), Montana (42), Nebraska (76), Nevada (72), New Hampshire (70), New Jersey (411), New Mexico (66), New York (1,183), North Carolina (463), North Dakota (39), Ohio (504), Oklahoma (102), Oregon (185), Pennsylvania (670), Rhode Island (46), South Carolina (145), South Dakota (31), Tennessee (290), Texas (887), Utah (102), Vermont (36), Virginia (284), Washington (370), West Virginia (75), Wisconsin (278), Wyoming (19)

¹ The data for oncologists include physicians who specified hematology, hematology/oncology, or medical oncology as their primary specialty in the CMS Physician Compare. Data were accessed from data.medicare.gov. Oncologists were grouped according to the state field of their practice address(es). Oncologists were counted once per state, with 491 of 12,940 oncologists (3.8%) represented in more than one state.

² Geographic shapefiles were accessed from census.gov/geographies/reference-files/time-series/geo/gazetteer-files.html. Colors were determined by quintiles of the data.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 6a. Oncologists per 100,000 Residents Age 55 Years or Older By State^{1,2}




Sources: CMS Physician Compare (April 2020 update), US Census Bureau Gazetteer Files (2019 update)

1 The data for oncologists include physicians who specified hematology, hematology/oncology, or medical oncology as their primary specialty in the CMS Physician Compare. Data were accessed from data.medicare.gov. Oncologists were grouped according to the state field of their practice address(es). Oncologists were counted once per state, with 491 of 12,940 oncologists (3.8%) represented in more than one state.

2 The data were normalized using 2018 population estimates from the US Census Bureau. Geographic shapefiles were accessed from census.gov/geographies/reference-files/time-series/geo/gazetteer-files.html. Residents age 55 years and older were chosen because they account for more than 75% of new cancer cases (see seer.cancer.gov/statfacts/html/all.html). Colors were determined by quintiles of the data.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 6b. Oncologists per 100,000 Residents Age 55 Years or Older By County^{1,2}




Sources: CMS Physician Compare (April 2020 update), US Census Bureau Gazetteer Files (2019 update)

1 The data for oncologists include physicians who specified hematology, hematology/oncology, or medical oncology as their primary specialty in the CMS Physician Compare. Data were accessed from data.medicare.gov. Oncologists were counted once per county, with 3,361 of 12,940 oncologists (26%) represented in more than one county.

2 The data were normalized using 2018 population estimates from the US Census Bureau. Geographic shapefiles were accessed from census.gov/geographies/reference-files/time-series/geo/gazetteer-files.html. Residents age 55 years and older were chosen because they account for more than 75% of new cancer cases (see seer.cancer.gov/statfacts/html/all.html). Colors were determined by quintiles of the data.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 7. Size and Distribution of Oncology Practices^{1,2}




Source: CMS Physician Compare (April 2020 update), U.S. Census Bureau Gazetteer Files (2019 update)

1 Points represent each of 1,698 practices in the US associated with at least one hematologist, hematologist/oncologist, or medical oncologist (primary specialty designation) in CMS Physician Compare. For practices with more than one oncologist practice location, the location with the most oncologists (and the most clinicians when tied) is displayed. Size of practice represents the number of hematologists and/or medical oncologists associated with that practice (not restricted to those practicing at the main site).

2 Geographic shapefiles were accessed from [census.gov/geographies/reference-files/time-series/geo/gazetteer-files.html](https://www.census.gov/geographies/reference-files/time-series/geo/gazetteer-files.html). Colors were determined by quintiles of the data.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 8. Rural and Non-Rural Oncology Practices^{1,2}




Sources: Medicare Physician Compare (April 2020 update), US Census Bureau Gazetteer Files, USDA Rural-Urban Continuum Codes

1 Points represent each of 1,698 practices in the US associated with at least one hematologist, hematologist/oncologist, or medical oncologist (primary specialty designation) in CMS Physician Compare. For practices with more than one oncologist practice location, the location with the most oncologists (and the most clinicians where tied) is displayed. Rural practices are those practices with a majority of hematologists and/or medical oncologists using a rural practice address, as classified by 2013 Rural-Urban Continuum Codes from the US Department of Agriculture, accessed from ers.usda.gov/data-products/rural-urban-continuum-codes.aspx.

2 Geographic shapefiles were accessed from census.gov/geographies/reference-files/time-series/geo/gazetteer-files.html. Colors were determined by quintiles of the data.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 9. Residents in Oncology Pipeline Programs¹




| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|-----------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Internal Medicine | 22,292 | 22,415 | 22,500 | 22,710 | 22,971 | 23,258 | 23,664 | 24,640 | 26,228 | 27,179 |
| Obstetrics/Gynecology | 4,842 | 4,884 | 4,945 | 4,931 | 4,942 | 5,018 | 5,061 | 5,143 | 5,346 | 5,453 |
| Pediatrics | 8,124 | 8,140 | 8,318 | 8,332 | 8,529 | 8,529 | 8,661 | 8,798 | 8,858 | 8,950 |

Source: JAMA Medical Education Issues

¹ The figures here represent the total number of residents in oncology pipeline programs that are accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 10. Percentage of Residents in Oncology Pipeline Programs Who Are Female¹




| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------------------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Total number of residents and fellows | 109,840 | 111,586 | 113,427 | 115,111 | 117,427 | 118,366 | 120,598 | 124,096 | 130,545 | 136,028 |
| Residents and fellows who are female | 50,485 | 51,475 | 52,512 | 53,083 | 54,065 | 54,445 | 55,410 | 56,667 | 59,242 | 61,980 |
| Percent female | 46.0 | 46.1 | 46.3 | 46.1 | 46.0 | 46.0 | 45.9 | 45.7 | 45.4 | 45.6 |
| Internal medicine residents | 22,292 | 22,415 | 22,500 | 22,710 | 22,971 | 23,258 | 23,664 | 24,640 | 26,228 | 27,179 |
| Internal med residents who are female | 9,978 | 10,028 | 10,030 | 9,863 | 9,984 | 10,045 | 10,223 | 10,550 | 10,995 | 11,474 |
| Percent female | 44.8 | 44.7 | 44.6 | 43.4 | 43.5 | 43.2 | 43.2 | 42.8 | 41.9 | 42.2 |
| Obstetrics/Gynecology residents | 4,842 | 4,884 | 4,945 | 4,931 | 4,942 | 5,018 | 5,061 | 5,143 | 5,346 | 5,453 |
| Ob/Gyn residents who are female | 3,858 | 3,974 | 4,053 | 4,062 | 4,079 | 4,130 | 4,206 | 4,251 | 4,426 | 4,550 |
| Percent female | 79.7 | 81.4 | 82.0 | 82.4 | 82.5 | 82.3 | 83.1 | 82.7 | 82.8 | 83.4 |
| Pediatrics residents | 8,124 | 8,140 | 8,318 | 8,332 | 8,529 | 8,529 | 8,661 | 8,798 | 8,858 | 8,950 |
| Pediatrics residents who are female | 5,945 | 5,914 | 6,092 | 6,123 | 6,233 | 6,223 | 6,331 | 6,401 | 6,367 | 6,449 |
| Percent female | 73.2 | 72.7 | 73.2 | 73.5 | 73.1 | 73.0 | 73.1 | 72.8 | 71.9 | 72.1 |

Source: JAMA Medical Education Issues

¹ The percentage of residents who are female is based on the total number of residents. For example, the percentage of internal medicine residents who are female is based on the total number of internal medicine residents. The denominator may include residents whose sex is not known.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 11. Percentage of Residents in Oncology Pipeline Programs Who Are USMDs¹




| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------------------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Total number of residents and fellows | 109,840 | 111,586 | 113,427 | 115,111 | 117,427 | 118,366 | 120,598 | 124,096 | 130,545 | 136,028 |
| Residents and fellows who are USMDs | 71,871 | 72,840 | 74,328 | 74,963 | 77,118 | 78,206 | 80,084 | 81,849 | 83,210 | 85,289 |
| Percent USMDs | 65.4 | 65.3 | 65.5 | 65.1 | 65.7 | 66.1 | 66.4 | 66.0 | 63.7 | 62.7 |
| Internal medicine residents | 22,292 | 22,415 | 22,500 | 22,710 | 22,971 | 23,258 | 23,664 | 24,640 | 26,228 | 27,179 |
| Internal med residents who are USMDs | 10,855 | 10,953 | 11,230 | 11,228 | 11,714 | 12,141 | 12,594 | 12,887 | 12,974 | 12,834 |
| Percent USMDs | 48.7 | 48.9 | 49.9 | 49.4 | 51.0 | 52.2 | 53.2 | 52.3 | 49.5 | 47.2 |
| Obstetrics/Gynecology residents | 4,842 | 4,884 | 4,945 | 4,931 | 4,942 | 5,018 | 5,061 | 5,143 | 5,346 | 5,453 |
| Ob/Gyn residents who are USMDs | 3,565 | 3,636 | 3,697 | 3,718 | 3,760 | 3,826 | 3,924 | 4,035 | 4,133 | 4,550 |
| Percent USMDs | 73.6 | 74.4 | 74.8 | 75.4 | 76.1 | 76.2 | 77.5 | 78.5 | 77.3 | 83.4 |
| Pediatrics residents | 8,124 | 8,140 | 8,318 | 8,332 | 8,529 | 8,529 | 8,661 | 8,798 | 8,858 | 8,950 |
| Pediatrics residents who are USMDs | 5,446 | 5,417 | 5,556 | 5,527 | 5,746 | 5,770 | 6,007 | 6,109 | 6,165 | 6,044 |
| Percent USMDs | 67.0 | 66.5 | 66.8 | 66.3 | 67.4 | 67.7 | 69.4 | 69.4 | 69.6 | 67.5 |

Source: JAMA Medical Education Issues

¹ The percentage of residents who are USMDs is based on the total number of residents. For example, the percentage of internal medicine residents who are USMDs is based on the total number of internal medicine residents. The denominator may include residents whose medical school is not known.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 12. Number of Physicians Who Completed an Oncology Pipeline Program¹




| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|-----------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Internal Medicine | 6,697 | 6,635 | 6,739 | 6,708 | 6,838 | 6,993 | 7,099 | 7,050 | 7,563 | 7,929 |
| Obstetrics/Gynecology | 1,168 | 1,178 | 1,180 | 1,219 | 1,209 | 1,202 | 1,221 | 1,234 | 1,276 | 1,303 |
| Pediatrics | 2,573 | 2,649 | 2,685 | 2,618 | 2,671 | 2,801 | 2,818 | 2,757 | 2,848 | 2,880 |

Source: JAMA Medical Education Issues

¹ These data represent the number of residents who completed a program in a given academic year. For example, data for 2016 correspond to residents who completed the program during the 2015-2016 academic year.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 13. Number of Physicians Who Applied for an Internal Medicine Subspecialty Fellowship



| | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2017 | 2018 | 2019 | 2020 |
|---|-------|-------|-------|-------|--------|--------|--------|--------|--------|--------|
| Total active fellowship applicants¹ | 7,774 | 8,249 | 8,653 | 9,297 | 10,032 | 10,337 | 10,873 | 11,277 | 11,996 | 12,512 |
| Oncology² | | | | | | | | | | |
| Medical oncology | 168 | 157 | 120 | 116 | 108 | 104 | 46 | 67 | 60 | 56 |
| Hematology | 128 | 118 | 99 | 101 | 100 | 108 | 84 | 77 | 77 | 82 |
| Hematology/Oncology | 741 | 742 | 750 | 689 | 725 | 693 | 729 | 788 | 758 | 809 |
| Other IM Subspecialty² | | | | | | | | | | |
| Cardiovascular Disease | 1,119 | 1,147 | 1,175 | 1,106 | 1,142 | 1,108 | 1,147 | 1,261 | 1,315 | 1,325 |
| Gastroenterology | 655 | 677 | 707 | 703 | 717 | 718 | 742 | 759 | 803 | 908 |
| Infectious Disease | 314 | 292 | 288 | 276 | 254 | 229 | 335 | 350 | 356 | 352 |
| Pulmonary Disease | 72 | 81 | 96 | 95 | 83 | 101 | 100 | 110 | 113 | 115 |
| Pulm. Disease and Critical Care I | 616 | 599 | 700 | 753 | 780 | 689 | 742 | 789 | 848 | 931 |
| Rheumatology | 225 | 240 | 244 | 230 | 245 | 304 | 332 | 322 | 366 | 344 |


Source: Results and Data: Specialties Matching Service. National Resident Matching Program. Accessed online at nrmp.org/fellowship-match-data.

1 The data here represent the number of physicians who registered for the NRMP's Specialties Matching Service (SMS) and submitted a rank order list of fellowship programs. The total number of applicants is affected by the number of programs that participate in the Match. To the extent that the number of programs participating increases, a corresponding increase in the total number of applicants might be expected. Data for 2020 represent the 2020 appointment year.

2 Please note that it is not possible to sum the number of applicants in one subspecialty to applicants in another subspecialty, as some applicants apply to more than one subspecialty. In other words, the same applicant may be counted in medical oncology and in hematology/oncology; summing those could result in double counting.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 14. Percentage of USMD Fellowship Applicants Who Matched to an Oncology Fellowship¹




| | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|--|------|------|------|------|------|------|------|------|------|------|
| USMDs who applied for a med onc fellowship | 47 | 57 | 25 | 37 | 34 | 43 | 9 | 8 | 3 | 7 |
| Number of USMDs who matched | 9 | 13 | 7 | 9 | 5 | 8 | 1 | 1 | 0 | 0 |
| Percent of USMDs who matched | 19.1 | 22.8 | 28.0 | 24.3 | 14.7 | 18.6 | 11.1 | 12.5 | 0.0 | 0.0 |
| USMDs who applied for a hem fellowship | 53 | 73 | 66 | 68 | 62 | 78 | 55 | 66 | 70 | 69 |
| Number of USMDs who matched | 11 | 9 | 13 | 13 | 10 | 8 | 13 | 12 | 13 | 14 |
| Percent of USMDs who matched | 20.8 | 12.3 | 19.7 | 19.1 | 16.1 | 10.3 | 23.6 | 18.2 | 18.6 | 20.3 |
| USMDs who applied for a hem/onc fellowship | 296 | 317 | 322 | 305 | 338 | 325 | 332 | 402 | 394 | 381 |
| Number of USMDs who matched | 238 | 259 | 258 | 262 | 285 | 284 | 287 | 332 | 344 | 334 |
| Percent of USMDs who matched | 80.4 | 81.7 | 80.1 | 85.9 | 84.3 | 87.4 | 86.4 | 82.6 | 87.3 | 87.7 |

Source: Results and Data: Specialties Matching Service. National Resident Matching Program. Accessed online at nrmp.org/fellowship-match-data.

¹ The figures here represent the number of USMDs who applied for a hematology, hematology/oncology, or clinical oncology fellowship in the the NRMP's Specialties Match and the percentage who matched to a hematology, hematology/oncology, or oncology program. The number of applicants is affected by the number of programs that participate in the Match. To the extent that the number of programs participating increases, a corresponding increase in the number of applicants might be expected. Data for 2020 represent the 2020 appointment year.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 15. Number of First Year Fellows in Internal Medicine Subspecialties¹



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--------------------------------------|------|------|------|------|------|------|------|------|------|------|
| Oncology (Composite) ² | 542 | 557 | 561 | 572 | 571 | 588 | 554 | 567 | 566 | 630 |
| Hematology | 20 | 20 | 19 | 10 | 13 | 12 | 15 | 10 | 7 | 10 |
| Hematology/Oncology | 473 | 497 | 501 | 516 | 520 | 547 | 509 | 540 | 541 | 596 |
| Medical Oncology | 49 | 40 | 41 | 46 | 38 | 29 | 30 | 17 | 18 | 24 |
| Other IM Subspecialty | | | | | | | | | | |
| Cardiovascular Disease | 797 | 779 | 785 | 851 | 840 | 829 | 797 | 845 | 884 | 952 |
| Gastroenterology | 422 | 454 | 462 | 468 | 458 | 473 | 485 | 505 | 499 | 532 |
| Infectious Disease | 339 | 350 | 364 | 359 | 363 | 344 | 329 | 325 | 357 | 358 |
| Nephrology | 438 | 419 | 426 | 441 | 437 | 418 | 432 | 410 | 385 | 399 |
| Pulm. Disease and Critical Care Med. | 434 | 449 | 473 | 490 | 511 | 496 | 553 | 544 | 566 | 672 |
| Rheumatology | 193 | 198 | 207 | 200 | 205 | 221 | 210 | 233 | 226 | 230 |


Source: JAMA Medical Education Issues

1 The data here represent the number of fellows in PY1 positions in internal medicine subspecialty programs accredited by the ACGME.

2 The data represent the total number of fellows (MDs and DOs) in hematology, hematology/oncology, and clinical oncology GME programs accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 16. Percentage of First Year IM Subspecialty Fellows by Subspecialty




| | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2015 | 2016 | 2017 | 2018 |
|---|------|------|------|------|------|------|------|------|------|------|
| Oncology (Composite)¹ | 14.2 | 14.5 | 14.3 | 14.0 | 13.8 | 14.5 | 13.8 | 13.7 | 13.5 | 14.0 |
| Medical oncology | 1.3 | 1.0 | 1.0 | 1.1 | 0.9 | 0.7 | 0.7 | 0.4 | 0.4 | 0.5 |
| Hematology | 0.5 | 0.5 | 0.5 | 0.2 | 0.3 | 0.3 | 0.4 | 0.2 | 0.2 | 0.2 |
| Hematology/Oncology | 12.4 | 12.9 | 12.8 | 12.6 | 12.6 | 13.5 | 12.7 | 13.1 | 12.9 | 13.3 |
| Other IM Subspecialty | | | | | | | | | | |
| Cardiovascular Disease | 20.9 | 20.2 | 20.1 | 20.9 | 20.3 | 20.4 | 19.9 | 20.4 | 21.0 | 21.2 |
| Gastroenterology | 11.1 | 11.8 | 11.8 | 11.5 | 11.1 | 11.7 | 12.1 | 12.2 | 11.9 | 11.8 |
| Infectious Disease | 8.9 | 9.1 | 9.3 | 8.8 | 8.8 | 8.5 | 8.2 | 7.9 | 8.5 | 8.0 |
| Pulm. Disease and Critical Care Med. | 11.4 | 11.7 | 12.1 | 12.0 | 12.4 | 12.2 | 13.8 | 13.2 | 13.5 | 14.9 |
| Rheumatology | 5.1 | 5.1 | 5.3 | 4.9 | 5.0 | 5.4 | 5.2 | 5.6 | 5.4 | 5.1 |

Source: JAMA Medical Education Issues

¹ The data represent the total number of fellows (MDs and DOs) in hematology, hematology/oncology, and clinical oncology GME programs accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 17. Percentage of Fellows in Internal Medicine Subspecialties Who Are Female



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|------|------|------|------|------|------|------|------|------|------|
| All residents and fellows ¹ | 46.0 | 46.1 | 46.3 | 46.1 | 46.0 | 46.0 | 45.9 | 45.7 | 45.4 | 45.6 |
| Internal medicine | 44.8 | 44.7 | 44.6 | 43.4 | 43.5 | 43.2 | 43.2 | 42.8 | 41.9 | 42.2 |
| Oncology (Composite) ² | 44.5 | 44.7 | 45.6 | 47.0 | 48.4 | 46.4 | 44.9 | 42.5 | 43.1 | 44.0 |
| Hematology | 49.0 | 34.9 | 42.2 | 38.1 | 47.1 | 51.4 | 48.4 | 33.3 | 43.8 | 59.1 |
| Hematology/Oncology | 44.5 | 45.4 | 45.9 | 47.2 | 48.5 | 46.8 | 45.2 | 42.9 | 43.3 | 43.8 |
| Medical Oncology | 42.2 | 39.2 | 43.3 | 48.0 | 46.6 | 35.6 | 38.8 | 34.5 | 34.2 | 42.9 |
| Other IM Subspecialty | | | | | | | | | | |
| Cardiovascular Disease | 21.3 | 22.2 | 21.7 | 21.5 | 21.6 | 21.5 | 21.4 | 21.3 | 22.9 | 24.5 |
| Endocrinology, Diabetes, Metabolism | 66.0 | 66.9 | 68.2 | 67.9 | 67.9 | 72.9 | 73.1 | 71.3 | 69.8 | 71.5 |
| Gastroenterology | 32.3 | 31.9 | 33.2 | 34.7 | 35.3 | 35.3 | 34.4 | 34.0 | 33.6 | 34.8 |
| Infectious Disease | 55.0 | 56.5 | 54.6 | 51.1 | 49.9 | 53.1 | 56.1 | 54.6 | 50.2 | 52.5 |
| Nephrology | 36.6 | 37.0 | 39.9 | 41.6 | 39.5 | 38.2 | 37.0 | 34.4 | 33.1 | 33.4 |
| Pulm Dis and Crit Care Med | 2.8 | 2.8 | 3.2 | 2.6 | 1.7 | 1.8 | 2.3 | 2.7 | 2.3 | 1.6 |
| Rheumatology | 66.0 | 65.7 | 64.7 | 64.5 | 59.3 | 58.1 | 61.2 | 60.2 | 60.8 | 62.4 |


Source: JAMA Medical Education Issues

1 The percentages are based on the number of fellows for whom sex is known.

2 The data represent the total number of fellows (MDs and DOs) in hematology, hematology/oncology, and clinical oncology GME programs accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 18. Percentage of Trainees Who Are Female



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|------|------|------|------|------|------|------|------|------|------|
| All residents and fellows ¹ | 46.0 | 46.1 | 46.3 | 46.1 | 46.0 | 46.0 | 45.9 | 45.7 | 45.4 | 45.6 |
| Internal medicine | 44.8 | 44.7 | 44.6 | 43.4 | 43.5 | 43.2 | 43.2 | 42.8 | 41.9 | 42.2 |
| Oncology (Composite) ² | 44.5 | 44.7 | 45.6 | 47.0 | 48.4 | 46.4 | 44.9 | 42.5 | 43.1 | 44.0 |
| Hematology | 49.0 | 34.9 | 42.2 | 38.1 | 47.1 | 51.4 | 48.4 | 33.3 | 43.8 | 59.1 |
| Hematology/Oncology | 44.5 | 45.4 | 45.9 | 47.2 | 48.5 | 46.8 | 45.2 | 42.9 | 43.3 | 43.8 |
| Medical Oncology | 42.2 | 39.2 | 43.3 | 48.0 | 46.6 | 35.6 | 38.8 | 34.5 | 34.2 | 42.9 |


Source: JAMA Medical Education Issues

1 The percentages are based on the number of fellows for whom sex is known.

2 The data represent the total number of fellows (MDs and DOs) in hematology, hematology/oncology, and clinical oncology GME programs accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 19. Percentage of Fellows in Internal Medicine Subspecialties Who Are IMGs



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|------|------|------|------|------|------|------|------|------|------|
| All residents and fellows ¹ | 27.4 | 27.3 | 26.7 | 26.7 | 25.9 | 25.3 | 24.6 | 23.9 | 23.5 | 23.0 |
| Internal medicine | 45.2 | 44.6 | 43.3 | 43.2 | 41.4 | 40.3 | 39.2 | 38.4 | 37.9 | 38.3 |
| Oncology (Composite) ² | 42.4 | 42.9 | 44.5 | 43.2 | 43.1 | 42.9 | 42.2 | 41.8 | 40.9 | 38.2 |
| Hematology | 30.6 | 41.9 | 37.8 | 26.2 | 26.5 | 17.1 | 32.3 | 23.8 | 37.5 | 18.2 |
| Hematology/Oncology | 42.0 | 42.4 | 44.0 | 42.5 | 42.3 | 42.7 | 41.9 | 42.1 | 41.0 | 38.1 |
| Medical Oncology | 52.6 | 51.0 | 55.7 | 60.8 | 63.6 | 58.9 | 51.3 | 40.0 | 36.8 | 50.0 |
| Select Other IM Subspecialty | | | | | | | | | | |
| Cardiovascular Disease | 35.2 | 36.7 | 38.4 | 40.0 | 41.5 | 41.5 | 42.0 | 41.9 | 40.7 | 38.2 |
| Endocrinology, Diabetes, Metabolism | 42.3 | 47.1 | 48.4 | 50.6 | 53.9 | 56.6 | 53.0 | 49.9 | 51.4 | 53.0 |
| Gastroenterology | 29.7 | 30.5 | 30.4 | 31.2 | 31.5 | 32.8 | 32.5 | 31.4 | 31.8 | 31.7 |
| Infectious Disease | 41.5 | 42.0 | 45.4 | 47.4 | 45.0 | 43.9 | 44.0 | 43.2 | 40.4 | 40.3 |
| Interventional Cardiovascular Disease | 47.9 | 41.4 | 48.4 | 47.0 | 45.8 | 47.7 | 51.6 | 52.4 | 51.7 | 45.7 |
| Nephrology | 54.6 | 59.2 | 63.6 | 65.8 | 68.0 | 68.3 | 65.8 | 65.8 | 67.7 | 66.2 |
| Pulm Dis and Crit Care Med | 45.2 | 45.6 | 46.8 | 47.5 | 47.6 | 44.4 | 44.0 | 43.2 | 42.0 | 40.9 |
| Rheumatology | 37.3 | 43.0 | 45.3 | 45.0 | 48.0 | 53.2 | 51.7 | 49.0 | 43.6 | 34.7 |


Source: JAMA Medical Education Issues

1 The percentages are based on fellows whose medical school is known. Physicians who graduated from medical schools in the U.S. territories or Canada are not considered IMGs.

2 The data represent the total number of fellows (MDs and DOs) in hematology, hematology/oncology, and clinical oncology GME programs accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 20a. Percentage of Fellows in IM Subspecialties Who Are Black or African American



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|------|------|------|------|------|------|------|------|------|------|
| All residents and fellows ¹ | 5.8 | 5.9 | 6.1 | 5.8 | 5.7 | 5.7 | 5.7 | 5.6 | 5.5 | 5.5 |
| Internal Medicine residents | 5.7 | 5.6 | 6.0 | 5.6 | 5.7 | 6.0 | 5.8 | 5.6 | 5.8 | 5.8 |
| Oncology (Composite) ² | 3.3 | 3.1 | 3.6 | 4.0 | 4.0 | 3.7 | 3.7 | 4.2 | 3.7 | 3.7 |
| Hematology | 4.1 | 4.7 | 4.4 | 7.1 | 2.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hematology/Oncology | 3.4 | 3.2 | 3.8 | 4.0 | 4.1 | 3.8 | 3.9 | 4.3 | 3.8 | 3.8 |
| Medical Oncology | 1.7 | 1.0 | 0.0 | 2.9 | 2.3 | 2.7 | 1.3 | 1.8 | 0.0 | 2.4 |
| Other IM Subspecialty | | | | | | | | | | |
| Cardiovascular Disease | 4.3 | 4.3 | 5.2 | 5.3 | 5.5 | 5.2 | 5.4 | 4.9 | 5.0 | 5.0 |
| Endocrinology, Diabetes, Metabolism | 4.6 | 4.8 | 5.8 | 3.9 | 2.7 | 4.5 | 4.6 | 4.6 | 5.1 | 3.8 |
| Gastroenterology | 4.5 | 4.6 | 5.2 | 4.5 | 5.0 | 4.8 | 5.8 | 5.2 | 5.4 | 4.7 |
| Infectious Disease | 8.5 | 6.9 | 7.5 | 7.0 | 7.2 | 6.2 | 7.0 | 7.9 | 6.6 | 5.8 |
| Nephrology | 4.9 | 5.9 | 7.0 | 7.5 | 7.2 | 6.4 | 7.1 | 8.4 | 8.2 | 6.2 |
| Pulm Dis and Crit Care Med | 3.0 | 3.0 | 3.0 | 3.6 | 3.9 | 4.3 | 4.1 | 4.5 | 4.1 | 3.6 |
| Rheumatology | 3.4 | 4.0 | 4.7 | 5.5 | 4.2 | 3.4 | 3.4 | 4.8 | 4.8 | 3.3 |


Source: JAMA Medical Education Issues

1 These figures represent the percentage of residents and fellows who are Black or African American. This includes people who are non-Hispanic and Black, as well as those who are Hispanic and Black. In 2014, the National GME Census imported self-designated race/ethnicity from Association of American Medical Colleges databases where available and thus introduced a "multiracial" category. Individuals citing more than one race are not included herein.

2 The data represent the total number of fellows (MDs and DOs) in hematology, hematology/oncology, and clinical oncology GME programs accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 20b. Percentage of Residents/Fellows Who Are Black or African American



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Total residents and fellows | 109,840 | 111,586 | 113,427 | 115,111 | 117,427 | 118,366 | 120,598 | 124,096 | 130,545 | 136,028 |
| Residents and fellows who are Black ¹ | 6,345 | 6,533 | 6,908 | 6,626 | 6,685 | 6,752 | 6,887 | 6,905 | 7,239 | 7,430 |
| Percent Black | 5.8 | 5.9 | 6.1 | 5.8 | 5.7 | 5.7 | 5.7 | 5.6 | 5.5 | 5.5 |
| Internal Medicine residents | 22,292 | 22,415 | 22,500 | 22,710 | 22,971 | 23,258 | 23,664 | 24,640 | 26,228 | 27,179 |
| IM residents who are Black | 1,264 | 1,250 | 1,339 | 1,278 | 1,304 | 1,385 | 1,379 | 1,391 | 1,522 | 1,584 |
| Percent Black | 5.7 | 5.6 | 6.0 | 5.6 | 5.7 | 6.0 | 5.8 | 5.6 | 5.8 | 5.8 |
| Oncology fellows (Composite) ² | 1,577 | 1,607 | 1,622 | 1,675 | 1,688 | 1,740 | 1,732 | 1,733 | 1,728 | 1,798 |
| Oncology fellows who are Black | 52 | 50 | 58 | 67 | 67 | 64 | 64 | 72 | 64 | 67 |
| Percent Black | 3.3 | 3.1 | 3.6 | 4.0 | 4.0 | 3.7 | 3.7 | 4.2 | 3.7 | 3.7 |
| Hematology fellows | 49 | 43 | 45 | 42 | 34 | 35 | 31 | 21 | 16 | 22 |
| Hematology fellows who are Black | 2 | 2 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Percent Black | 4.1 | 4.7 | 4.4 | 7.1 | 2.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hematology/Oncology fellows | 1,412 | 1,462 | 1,480 | 1,531 | 1,566 | 1,632 | 1,621 | 1,657 | 1,674 | 1,734 |
| Hem/Onc fellows who are Black | 48 | 47 | 56 | 61 | 64 | 62 | 63 | 71 | 64 | 66 |
| Percent Black | 3.4 | 3.2 | 3.8 | 4.0 | 4.1 | 3.8 | 3.9 | 4.3 | 3.8 | 3.8 |
| Medical Oncology fellows | 116 | 102 | 97 | 102 | 88 | 73 | 80 | 55 | 38 | 42 |
| Medical Onc. fellows who are Black | 2 | 1 | 0 | 3 | 2 | 2 | 1 | 1 | 0 | 1 |
| Percent Black | 1.7 | 1.0 | 0.0 | 2.9 | 2.3 | 2.7 | 1.3 | 1.8 | 0.0 | 2.4 |


Source: JAMA Medical Education Issues

1 These figures represent the percentage of residents and fellows who are Black or African American. This includes people who are non-Hispanic and Black, as well as those who are Hispanic and Black. In 2014, the National GME Census imported self-designated race/ethnicity from Association of American Medical Colleges databases where available and thus introduced a "multiracial" category. Individuals citing more than one race are not included herein.

2 The data represent the total number of fellows (MDs and DOs) in hematology, hematology/oncology, and clinical oncology GME programs accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 21a. Percentage of Fellows in Internal Medicine Subspecialties Who Are Hispanic or Latino



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|------|------|------|------|------|------|------|------|------|------|
| All residents and fellows ¹ | 8.0 | 7.9 | 7.9 | 7.5 | 7.5 | 7.6 | 7.6 | 7.6 | 7.8 | 8.1 |
| Internal Medicine residents | 9.1 | 8.7 | 8.7 | 7.6 | 7.7 | 7.8 | 7.8 | 7.5 | 7.7 | 8.3 |
| Oncology (Composite)² | | | | | | | | | | |
| Hematology | 12.2 | 4.7 | 2.2 | 7.1 | 5.9 | 5.7 | 0.0 | 0.0 | 0.0 | 4.5 |
| Hematology/Oncology | 6.8 | 7.5 | 6.4 | 5.7 | 5.0 | 5.3 | 5.6 | 5.7 | 5.4 | 6.1 |
| Medical Oncology | 9.5 | 7.8 | 7.2 | 5.9 | 10.2 | 6.8 | 5.0 | 3.6 | 0.0 | 0.0 |
| Other IM Subspecialty | | | | | | | | | | |
| Cardiovascular Disease | 6.3 | 6.3 | 6.7 | 7.5 | 6.8 | 7.1 | 6.8 | 7.1 | 6.4 | 5.3 |
| Endocrinology, Diabetes, Metabolism | 9.4 | 10.4 | 10.5 | 8.2 | 11.3 | 13.5 | 11.7 | 11.1 | 11.9 | 13.1 |
| Gastroenterology | 7.5 | 7.3 | 7.9 | 8.0 | 8.0 | 8.7 | 7.6 | 6.8 | 6.6 | 6.1 |
| Infectious Disease | 11.6 | 12.1 | 12.5 | 12.6 | 12.3 | 13.0 | 11.4 | 12.7 | 11.4 | 10.2 |
| Nephrology | 6.5 | 6.9 | 7.8 | 8.3 | 7.2 | 8.3 | 8.9 | 8.5 | 7.4 | 8.3 |
| Pulm Dis and Crit Care Med | 10.6 | 10.2 | 10.4 | 9.4 | 8.9 | 8.2 | 6.4 | 6.2 | 6.0 | 6.6 |
| Rheumatology | 10.6 | 8.7 | 10.7 | 9.3 | 6.8 | 7.0 | 7.9 | 7.7 | 7.1 | 6.8 |


Source: JAMA Medical Education Issues

1 These figures represent the proportion of residents and fellows in ACMGE-accredited programs who are Hispanic or Latino. People who are Hispanic or Latino can be of any race.

2 The data represent the total number of fellows (MDs and DOs) in hematology, hematology/oncology, and clinical oncology GME programs accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 21b. Percentage of Residents and Fellows Who Are Hispanic or Latino



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Total residents and fellows | 109,840 | 111,586 | 113,427 | 115,111 | 117,427 | 118,366 | 120,598 | 124,096 | 130,545 | 136,028 |
| Residents and fellows who are Hispanic ¹ | 8,792 | 8,832 | 9,013 | 8,625 | 8,780 | 9,048 | 9,135 | 9,409 | 10,180 | 10,963 |
| Percent Hispanic | 8.0 | 7.9 | 7.9 | 7.5 | 7.5 | 7.6 | 7.6 | 7.6 | 7.8 | 8.1 |
| Internal Medicine residents | 22,292 | 22,415 | 22,500 | 22,710 | 22,971 | 23,258 | 23,664 | 24,640 | 26,228 | 27,179 |
| IM residents who are Hispanic | 2,026 | 1,942 | 1,953 | 1,732 | 1,762 | 1,814 | 1,852 | 1,854 | 2,029 | 2,258 |
| Percent Hispanic | 9.1 | 8.7 | 8.7 | 7.6 | 7.7 | 7.8 | 7.8 | 7.5 | 7.7 | 8.3 |
| Oncology fellows (Composite) ² | 1,577 | 1,607 | 1,622 | 1,675 | 1,688 | 1,740 | 1,732 | 1,733 | 1,728 | 1,798 |
| Oncology fellows who are Hispanic | 113 | 120 | 102 | 97 | 90 | 93 | 95 | 96 | 90 | 107 |
| Percent Hispanic | 7.2 | 7.5 | 6.3 | 5.8 | 5.3 | 5.3 | 5.5 | 5.5 | 5.2 | 6.0 |
| Hematology fellows | 49 | 43 | 45 | 42 | 34 | 35 | 31 | 21 | 16 | 22 |
| Hematology fellows who are Hispanic | 6 | 2 | 1 | 3 | 2 | 2 | 0 | 0 | 0 | 1 |
| Percent Hispanic | 12.2 | 4.7 | 2.2 | 7.1 | 5.9 | 5.7 | 0.0 | 0.0 | 0.0 | 4.5 |
| Hematology/Oncology fellows | 1,412 | 1,462 | 1,480 | 1,531 | 1,566 | 1,632 | 1,621 | 1,657 | 1,674 | 1,734 |
| Hem/Onc fellows who are Hispanic | 96 | 110 | 94 | 88 | 79 | 86 | 91 | 94 | 90 | 106 |
| Percent Hispanic | 6.8 | 7.5 | 6.4 | 5.7 | 5.0 | 5.3 | 5.6 | 5.7 | 5.4 | 6.1 |
| Medical Oncology fellows | 116 | 102 | 97 | 102 | 88 | 73 | 80 | 55 | 38 | 42 |
| Medical Onc. fellows who are Hispanic | 11 | 8 | 7 | 6 | 9 | 5 | 4 | 2 | 0 | 0 |
| Percent Hispanic | 9.5 | 7.8 | 7.2 | 5.9 | 10.2 | 6.8 | 5.0 | 3.6 | 0.0 | 0.0 |


Source: JAMA Medical Education Issues

1 These figures represent the proportion of residents and fellows in ACMGE-accredited programs who are Hispanic or Latino. People who are Hispanic or Latino can be of any race.

2 The data represent the total number of fellows (MDs and DOs) in hematology, hematology/oncology, and clinical oncology GME programs accredited by the ACGME.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 22. New Entrants to the Oncology Workforce (Fellows Completing GME and Board Exam Test Takers)



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|------|------|------|------|------|------|------|------|------|------|
| Fellows who completed an oncology program | 523 | 510 | 547 | 549 | 576 | 563 | 586 | 587 | 588 | 601 |
| Hematology | 21 | 13 | 9 | 13 | 10 | 13 | 18 | 5 | 7 | 9 |
| Hematology/Oncology | 453 | 456 | 497 | 480 | 529 | 516 | 539 | 562 | 550 | 572 |
| Medical Oncology | 49 | 41 | 41 | 56 | 37 | 34 | 29 | 20 | 31 | 20 |


| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|------|------|------|------|------|------|------|------|------|------|
| Physicians who took certifying exam for first time ² | | | | | | | | | | |
| Hematology | 402 | 421 | 376 | 413 | 466 | 427 | 445 | 477 | 492 | 470 |
| Medical Oncology | 547 | 538 | 544 | 513 | 562 | 562 | 546 | 582 | 597 | 589 |

1 The number of fellows completing a hematology, hematology/oncology, or oncology program were obtained from the ACGME website, accessed from acgme.org/acgmeweb/tabid/259/Publications/GraduateMedicalEducationDataResourceBook.aspx. The year corresponds to the year of graduation. For example, fellows graduating after the 2015-2016 Academic Year are represented in 2016.

2 The number of first time test-takers in Hematology and Medical Oncology were obtained from the American Board of Internal Medicine website, available at abim.org/about/examInfo/data-pass-rates.aspx.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 23. Estimated Number of New Cancer Cases (in 1000s) by Sex¹




| | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|------------------------------------|------|------|------|------|------|------|------|------|------|------|
| Estimated new cancer cases - Males | 822 | 848 | 855 | 855 | 848 | 841 | 836 | 856 | 871 | 894 |
| Estimated new cancer cases - Femal | 774 | 791 | 806 | 810 | 810 | 844 | 853 | 879 | 891 | 913 |

1 The estimated number of new cases comes from the American Cancer Society. Cancer Facts and Figures. Accessed online at cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures.html. The number of estimated new cancer cases exclude basal and squamous cell skin cancers and in situ carcinomas except urinary bladder. Estimated new cases are rounded to the nearest 10th and are based on incidences rates from 41 states and the District of Columbia as reported by the North American Association of Central Cancer Registries, representing about 85% of the US population.

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 24. Five-Year Relative Cancer Survival Rates by Year of Diagnosis



5-year relative survival rate by year of diagnosis¹


| | | | | | | | | | |
|------|------|------|------|------|------|------|------|------|------|
| 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
| 66.8 | 67.3 | 67.7 | 68.7 | 69.4 | 69.1 | 69.6 | 69.5 | 69.7 | 69.0 |

Source: Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.

¹ The five-year cancer survival rates represent the proportion of patients surviving cancer 5 years after diagnosis, adjusted to remove all causes of death except cancer. These rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Key Trends in Tracking Supply of and Demand for Oncologists

Figure 25. Number of People With a History of Cancer (in 1000s)



| | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|--|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| People with a history of cancer (in 1000s) | 11,958 | 12,553 | 13,028 | 13,397 | 13,776 | 14,140 | 14,739 | 15,113 | 15,339 | 15,761 |
| Cancer survivors, 5-year limited duration | 4,250 | 4,357 | 4,511 | 4,595 | 4,660 | 4,684 | 5,327 | 5,364 | 4,618 | 4,695 |

Source: Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.

1 These figures represent the number of people with a history of cancer who were alive in the corresponding year. Some of these individuals were cancer-free, while others still had evidence of cancer.

2 The number of cancer survivors (5-year limited duration) represents the US cancer prevalence counts based on cancer prevalence proportions from the SEER 9 registries and US population estimates. Prevalence estimates here refer to the first invasive tumor ever that was diagnosed within the prior 5 years.